Symbols

NAGE

Niagen·NASDAQ

--(--)

NAGE fundamentals

NAGE Q4 2025 Earnings

Niagen (NAGE) released its earnings on Mar 4, 2026: revenue was 33.84M (YoY +16.19%), beat estimates; EPS was 0.05 (YoY -44.44%), beat estimates.

Revenue / YoY

33.84M

+16.19%

EPS / YoY

0.05

-44.44%

Report date

Mar 4, 2026

NAGE Earnings Call Summary for Q4,2025

Record Financial Performance: 30% YoY revenue growth to $129.4M, $17.4M net income, and $64.8M cash.
2026 Growth Drivers: 10-15% revenue growth from e-commerce, IV injections (launching H1 2026), and cosmetics partnerships.
Scientific Leadership: 29 new studies validate NR's anti-aging benefits, with NR shown superior to NMN in clinical trials.
Strategic Moves: Sold non-core ChromaDex business, filed lawsuit against FDA NMN reversal, and expanded IP portfolio.
Financial Strength: 64.3% gross margin, $20.4M EBITDA, and no debt.

Earnings

EPS

Revenue

Revenue & Expenses

NAGE has released its 2025 Q4 earnings report, with revenue of 33.84M, reflecting a YoY change of 16.19%, and net profit of 4.13M, showing a YoY change of -42.44%. The Sankey diagram below clearly presents NAGE's revenue sources and cost distribution.

Key Indicators

Niagen (NAGE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Niagen (NAGE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Niagen (NAGE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Niagen (NAGE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown